Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Scott B. Reeder
Cedars Sinai Medical Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Elucent
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
An outside activity has a nexus with an individual's research activities if the outside activity arises from, relies upon or is related to the academic expertise that qualifies that individual to participate in federally funded research or human subjects research. The Institution has reasonably determined that the significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research and so requires management.
Developing a MRI-guided Disease-Modifying Therapy for Post Infarction Chronic Heart Failure
PROJECT NARRATIVE Adverse remodeling of the heart is the key factor driving the post-infarction chronic heart failure epidemic in the US. The presence of persistent microvascular obstruction (PMO, the lack of blood flow in the microvascular bed despite reestablishment of blood flow in the epicardial arteries) in acute myocardial infarction (MI) has been identified as the best predictor of adverse remodeling leading to death or hospitalization in chronic phase of MI; however, how PMO contributes to adverse remodeling or how this may be prevented is unknown. This proposal aims to develop new mechanistic insights and test a rapidly translatable therapy in a clinically relevant animal model of MI.
Filed on November 22, 2017.
Tell us what you know about Scott B. Reeder's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Scott B. Reeder”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Scott B. Reeder | University of Wisconsin Madison | Conflict of Interest | Neuwave Inc. | $20,000 - $39,999 |
| Scott B. Reeder | University of Wisconsin Madison | Conflict of Interest | Neuwave Inc. | $20,000 - $39,999 |
| Scott B. Reeder | Cedars Sinai Medical Center | Conflict of Interest | Reveal Pharmaceuticals | $20,000 - $39,999 |
| Scott B. Reeder | Cedars Sinai Medical Center | Conflict of Interest | Calimetrix | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.